BioPharmSignal logoBioPharmSignal

Biotech News

Amgen wins FDA approval for late-stage oncology treatment

Amgen Inc. (AMGN)amgen.comFDA / regulatory

Amgen (AMGN) appears in the live feed after an FDA catalyst that can change the stock's tone quickly.

The source domain is amgen.com. BioPharmSignal keeps the ticker, timestamp, and source together so readers can move from signal to source without leaving the flow.

The original release is available below in a new tab so you can continue into the full source when needed.

Related news

REGNRegeneron Pharmaceuticals2026-06-22 11:00 EST

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

REPLReplimune Group2026-08-06 20:00 EST

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

RVMDRevolution Medicines2026-07-22 20:05 EST

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

REPLReplimune Group2026-07-30 22:15 EST

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

INBXInhibrx2026-06-15 13:15 EST

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

ALVOAlvotech2026-06-08 08:00 EST

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

ARWRArrowhead Pharmaceuticals2026-08-04 20:00 EST

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

ALVOAlvotech2026-07-29 13:32 EST

Alvotech announces successful closure of FDA inspection of manufacturing facility

ELVNEnliven Therapeutics2026-06-11 12:00 EST

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

View all latest news

Amgen Inc.

Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.

Recent company news

AMGNamgen.com2026-04-03 09:15 EST

FDA approves late-stage oncology treatment

AMGNamgen.com2026-04-01 08:05 EST

Management commentary keeps pipeline priorities in focus

AMGNnewswire2026-03-28 16:20 EST

Investors watch oncology and cardiometabolic launch cadence

AMGNsec.gov2026-03-21 07:50 EST

Regulatory calendar keeps Amgen in the spotlight

AMGNconference2026-03-15 10:10 EST

Pipeline updates reinforce the commercial-stage narrative

Stock data

Close
404.85 USD
Market cap
177.16B USD
Exchange
NASDAQ
Sector
Generics, Biopharma, Oncology, Immunotherapy
Location
Thousand Oaks, California